Treatment of patients with fibromyomata by Zoladex produces suppression of ovarian function. Receptor changes also occur in fibroids of women treated with Zoladex. The concentration of oestradiol receptors is significantly higher, whilst that of epidermal growth factor and progesterone is significantly lower.
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 07/02/2016 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/2533146